文献速递中药与中成药合理使用中医内科

丹参与葛根复方与华法林及阿司匹林联用的安全性初探:健康人体试验

Is it safe to take Radix Salvia Miltiorrhiza - Radix Pueraria Lobate product with warfarin and aspirin? A pilot study in healthy human subjects.
PubMed 文献 · J Ethnopharmacol · 2020-07-28

该研究在14名健康受试者中开展为期5天、多剂量、五阶段临床试验,各阶段间设2周洗脱期,考察丹参与葛根复方(DG)与阿司匹林或华法林联用的药动学和药效学相互作用。结果显示DG与阿司匹林或华法林联用可致显著草药-药物相互作用,表现为阿司匹林AUC0→t中度升高、7-羟基华法林AUC0→t降低,以及丹酚酸B等指标变化。

要点

  • DG与阿司匹林联用可中度升高阿司匹林AUC0→t并降低血栓素B2。
  • DG与华法林联用可降低7-羟基华法林AUC0→t并减弱可溶性血栓调节蛋白诱导。
  • 健康受试者中观察到显著药动学和药效学草药-药物相互作用。

核心结论

  • DG与阿司匹林或华法林联用在健康受试者中可导致显著的药动学和药效学草药-药物相互作用。

研究设计与样本

  • 5天、多剂量、五阶段临床试验,n=14,各阶段间设2周洗脱期,受试者接受不同药物组合。
  • 采集血浆样本进行药动学评价,全血样本进行药效学评价,并开展体外机制研究。

主要发现

  • DG与阿司匹林或华法林联用可分别导致阿司匹林AUC0→t中度升高和7-羟基华法林AUC0→t降低。
  • DG与华法林联用后丹酚酸B(DSS)全身暴露显著增加。
  • DG与阿司匹林联用后全身血栓素B2浓度降低,可能与阿司匹林暴露增加及DSS、阿司匹林和水杨酸对COX抑制的协同效应有关。
  • DG与华法林联用后华法林诱导的可溶性血栓调节蛋白升高出现减弱,部分归因于DSS的COX-2抑制作用。

临床怎么用

  • 临床联用丹参与葛根复方与阿司匹林或华法林时,应关注潜在药动学和药效学相互作用。

局限性

  • 本研究为健康受试者中的初探性试验,样本量有限(n=14),结论外推至患者人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Radix Salvia Miltiorrhiza (Danshen) and Radix Pueraria Lobate (Gegen) are officially listed in the Chinese Pharmacopoeia and have long been used together as a Compound Chinese Traditional Medicine (CCTM) for treatment of coronary heart diseases, which are often co-administered with aspirin or warfarin to patients suffering from cardiovascular diseases. AIM OF STUDY: Since significant pharmacokinetic and pharmacodynamic interactions between Danshen-Gegen (DG) formula and aspirin/warfarin have been observed in our previous rat studies, the current study was proposed aiming to further verify such pharmacokinetic and pharmacodynamic interactions in healthy human subjects and explore related mechanisms. MATERIALS AND METHODS: A 5-day, multiple dose, five-session clinical trial has been carried out (n = 14) with 2-week washout periods between sessions, during which the subjects would receive different combinations of the medications. Plasma samples were collected for pharmacokinetic evaluation, and whole blood samples were collected for pharmacodynamic evaluation. In addition, an in-vitro mechanistic study is conducted to investigate the role of danshensu on the anti-thrombotic and anti-platelet aggregation effects of warfarin and aspirin respectively. RESULTS: Significant pharmacokinetic and pharmacodynamic herb-drug interactions were observed in healthy human subjects. pharmacokinetically, co-administration of DG with aspirin or warfarin could lead to a moderately increased AUC0→t of aspirin and a decreased AUC0→t of 7-hydroxyl warfarin respectively. The systemic exposure of danshensu (DSS, the marker component of DG) would be significantly increased after co-administration with warfarin. Pharmacodynamically, a reduction in systemic thromboxane B2 concentration was noticed after administration of DG with aspirin, which could be associated with the increased systemic exposure of aspirin and the synergistic effect of danshensu, aspirin and salicylic acid on cyclooxygenase (COX) inhibition. An offset on the warfarin induced soluble thrombomodulin induction was observed after its co-administration with DG, which could be partially attributed to the COX-2 inhibition effect of danshensu. CONCLUSION: Our results indicated that co-administration of DG with aspirin/warfarin would lead to significant pharmacokinetic and pharmacodynamic herb-drug interactions in healthy human subjects.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Yang M, Ho NJ, et al. Is it safe to take Radix Salvia Miltiorrhiza - Radix Pueraria Lobate product with warfarin and aspirin? A pilot study in healthy human subjects. J Ethnopharmacol. 2020. PMID: 32736050. doi:10.1016/j.jep.2020.113151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。